Efficacy and safety of lenalidomide in the treatment of B-cell non-Hodgkin lymphoma
Abstract Background The combination of rituximab and chemotherapy is a first-line treatment for patients with B-cell non-Hodgkin lymphoma. Lenalidomide is an immunomodulatory drug that has shown promising properties and activity in a variety of hematological malignancies. This study evaluated the ef...
Uloženo v:
| Hlavní autoři: | , , , , , , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer
2024-04-01
|
| Edice: | Discover Oncology |
| Témata: | |
| On-line přístup: | https://doi.org/10.1007/s12672-024-00965-7 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|